EClinicalMedicine October 2020 PMID 33150319

Psilocybin-assisted group therapy for demoralized older long-term AIDS survivor men: An open-label safety and feasibility pilot study.

Brian T Anderson, Alicia Danforth, Prof Robert Daroff, Christopher Stauffer, Eve Ekman, Gabrielle Agin-Liebes, Alexander Trope, Matthew Tyler Boden, Prof James Dilley, Jennifer Mitchell, Joshua Woolley

Download social card

Mentions

Peak: 13 in Dec 2020

across 5 sources since Sep 2020

Extended reach

284,450

potential audience

Total likes

240

Video views

6,902

Mentions per month

Sep 2020 – Sep 2025

Where it's discussed

X / Twitter56 posts
News10 articles
Blogs6 articles
YouTube3 videos
Facebook3 posts

AI synopsis

What people are saying

The overall tone reflects a strong interest in the therapeutic potential of psilocybin, with posts emphasizing the groundbreaking nature of the study, such as references to its pioneering status and discussion of attachment issues, and some responses delve into related psychological mechanisms, demonstrating a moderate level of engagement and recognition of its importance.

AgreementModerate agreement

Most discussions support the positive potential of psilocybin-assisted therapy for demoralized AIDS survivors, reflecting a shared belief in its benefits.

InterestHigh interest

Posts demonstrate high curiosity, citing specific studies, referencing investigative series, and emphasizing scientific advancements.

EngagementModerate engagement

Comments show some depth by referencing previous research, mentioning variables like attachment anxiety, and discussing the broader implications of psychedelic therapy.

ImpactModerate impact

The conversations highlight the significance of this research in advancing mental health treatments, though mostly within academic and activist circles, indicating moderate impact overall.

Abstract in brief

This study explored whether psilocybin-assisted group therapy is safe and feasible for older long-term AIDS survivor men who experience high levels of demoralization, and it found no serious adverse reactions, indicating it may be safe.
The participants showed a significant reduction in demoralization levels from baseline to a 3-month follow-up, suggesting that this therapy could effectively help alleviate feelings of demoralization in this population.
The findings support the idea that group therapy combined with psilocybin could be an efficient way to deliver psychological support, especially for populations dealing with traumatic loss and emotional distress.]

Read the full abstract

All mentions

Complexity of Brain Activity Induced by Psychedelics: LSD & Psilocybin

Este vídeo faz parte da disciplina de Química e Farmacologia de Produtos Naturais no PPGCF UFS. Exploramos como alucinógenos como LSD e psilocibina aumentam a complexidade da atividade cerebral, abordando suas…

Mairim Serafini · Oct 19, 2020 3,309 views

MDMA in Group Therapy: Enhancing PTSD Treatment Outcomes

Discover the evolution of MDMA psychedelic-assisted group therapy for PTSD with Dr. Chris Stauffer. Explore how it influences group dynamics and therapy outcomes, highlighting its potential to expand access to these…

Psychedelic Support · Oct 23, 2024 2,946 views

Insights on Psychedelics in Pharmacy with Dr. Kelan Thomas

In this episode of the Psychedelic Pharmacist Interview Series, Dr. Kelan Thomas discusses his unique career path and the future of psychedelics in pharmacy. An expert in psychiatric pharmacotherapy, Dr. Thomas shares…

Psychedelic Pharmacists Association · Dec 19, 2021 647 views

SeaÐale

@seadale1 · X

We need a psilocybin study for the #LongCovid patients! https://t.co/QRGf45wtRs

Sep 21, 2025 · 5 likes · 1,617 followers View post →

Naoko Bishop /licensed psilocybin facilitator

@NaokoBishop · X

ポートランドで行われているMDMAのグループセラピー研究についての講演会があり、そちらの動画がアップされした。英語ですが、セッションのあり方（インテイクまでの流れやその後のインタグレーションの日程など）や研究の効果など、興味深いお話しです。https://t.co/cnhuHG8jRO

Oct 29, 2024 · 3 likes · 360 followers View post →

Robin Carhart-Harris

@RCarhartHarris · X

@VinaSean https://t.co/xyB6io3vKL https://t.co/AXXqPjisgu https://t.co/SCDC5fFEeW

Aug 30, 2024 · 64,914 followers View post →

kayla greenstien

@Kgreenstien · X

@sarparastmd The trial you’re mentioning wasn’t for PTSD, it was group use of psilocybin for demoralisation https://t.co/DA2sEIGSCZ

May 19, 2023 · 964 followers View post →

UCSF AME CENTER

@UCSFAME · X

The use of psychedelics for therapeutics is an up and coming field. Exciting work by AME’s Eve Ekman shows that Psilocybin therapy can have significant effects on demoralization among older long term AIDS survivor men. Learn more: https://t.co/jyBjdpHQzp https://t.co/8Ty5QZto5Z

Jan 28, 2022 · 1 like · 766 followers View post →

DomDom

@Kevin_Lanzo · X

RT @MichaelHaichin: Also, check out the first instalment of the Psychedelic Pharmacists Interview Series! https://t.co/Fbf5dyFBWY I spoke w…

Dec 23, 2021 · 1 share · 46 followers View post →

Michael Haichin

@MichaelHaichin · X

Also, check out the first instalment of the Psychedelic Pharmacists Interview Series! https://t.co/Fbf5dyFBWY I spoke with Dr. Kelan Thomas about his unique career path, the future of psychedelics in pharmacy, and more.

Dec 22, 2021 · 2 likes · 1 share · 3,678 followers View post →

Dr. Emily Kulpa, PharmD

@emkulpa · X

RT @PsilocybinAlpha: Psychedelic Pharmacists Interview Series: Dr. Kelan Thomas Dr. Thomas speaks with Psychedelic Pharmacists Association…

Dec 21, 2021 · 2 shares · 645 followers View post →

Psychedelic Pharmacists Association

@PsyPharmacists · X

RT @PsilocybinAlpha: Psychedelic Pharmacists Interview Series: Dr. Kelan Thomas Dr. Thomas speaks with Psychedelic Pharmacists Association…

Dec 20, 2021 · 2 shares · 2,048 followers View post →

Psychedelic Alpha

@Psyched_Alpha · X

Psychedelic Pharmacists Interview Series: Dr. Kelan Thomas Dr. Thomas speaks with Psychedelic Pharmacists Association (@PsyPharmacists) co-founder Dr. Michael Haichin about his unique career path, the future of psychedelics in pharmacy, and more. https://t.co/XnTA30Y3Qw

Dec 20, 2021 · 4 likes · 2 shares · 20,497 followers View post →

Francisco

@Giving_It_Raw · X

Psilocybin-assisted group therapy for demoralized older long-term AIDS... https://t.co/btaAHrkwmR

Aug 1, 2021 · 1,089 followers View post →

Views on Drugs

@ViewsOnDrugsBot · X

RT @ViewsOnDrugsBot: #Psilocybin-assisted group #therapy for demoralized older long-term AIDS survivor men: An open-label safety and feasib…

Jun 24, 2021 · 2 shares · 2,066 followers View post →

UCSF Psychiatry and Behavioral Sciences

@UCSFPsychiatry · X

#Research reading: #Psilocybin-assisted group therapy for demoralized older long-term #AIDS survivor men: An open-label safety and feasibility pilot study - https://t.co/9Fl9xx7nYq

Jun 23, 2021 · 1 like · 5,297 followers View post →

Blossom

@blossomact · X

The interviews are with participants from last years' study that might have laid the groundwork for group therapy with psychedelics (in the current century). https://t.co/ppHxfK2H9A

Jun 17, 2021 · 3,362 followers View post →

TrPR Program @ UCSF

@TrPR_Program · X

We explored the therapeutic trajectories of individuals undergoing psilocybin-assisted group therapy in our previous published trial https://t.co/3gGjH8g2gY using interpretive phenomenological analysis.

Jun 14, 2021 · 1 like · 1,489 followers View post →

Josh Woolley MD/PhD

@thebandlab · X

@JacobSAday1 @EKCaldwell Fascinating work! Did you see this paper? https://t.co/oMhOkDVENP We found attachment anxiety and avoidance predicted aspects of the psychedelic experience. Maybe for the next review?

Apr 4, 2021 · 1,971 followers View post →

Views on Drugs

@ViewsOnDrugsBot · X

RT @drugSciBot: #Psilocybin-assisted group #therapy for demoralized older long-term AIDS survivor men: An open-label safety and feasibility…

Mar 1, 2021 · 1 share · 2,066 followers View post →

Views on Drugs

@ViewsOnDrugsBot · X

#Psilocybin-assisted group #therapy for demoralized older long-term AIDS survivor men: An open-label safety and feasibility pilot study https://t.co/9TRBqeKuGS

Mar 1, 2021 · 1 like · 1 share · 2,066 followers View post →

Views on Drugs

@ViewsOnDrugsBot · X

RT @drugSciBot: #Psilocybin-assisted group #therapy for demoralized older long-term AIDS survivor men: An open-label safety and feasibility…

Jan 27, 2021 · 1 share · 2,066 followers View post →

Views on Drugs

@ViewsOnDrugsBot · X

#Psilocybin-assisted group #therapy for demoralized older long-term AIDS survivor men: An open-label safety and feasibility pilot study https://t.co/SDU3E1LCZM

Jan 27, 2021 · 1 share · 2,066 followers View post →

eClinicalMedicine – The Lancet Discovery Science

@eClinicalMed · X

1/4 Highlights of our 2020 content: @DerekEditor invites you to read: “Psilocybin-assisted group therapy for demoralized #older long-term #AIDS survivor men: An open-label safety and feasibility pilot study” by Brian Anderson and colleagues @UCSF. https://t.co/YpECq7AmSh

Dec 29, 2020 · 7,628 followers View post →

Views on Drugs

@ViewsOnDrugsBot · X

RT @drugSciBot: #Psilocybin-assisted group #therapy for demoralized older long-term AIDS survivor men: An open-label safety and feasibility…

Dec 28, 2020 · 2 shares · 2,066 followers View post →

Views on Drugs

@ViewsOnDrugsBot · X

#Psilocybin-assisted group #therapy for demoralized older long-term AIDS survivor men: An open-label safety and feasibility pilot study https://t.co/FqhQVojQmP

Dec 28, 2020 · 1 like · 2 shares · 2,066 followers View post →

Blossom

@blossomact · X

The original study was the first modern study that used group therapy and studied demoralization in AIDS patients. https://t.co/ppHxfK2H9A

Dec 17, 2020 · 3,362 followers View post →

Michel Blanc

@Blanc07Michel · X